Drug Topics
JUNE 19, 2025
The FDA approved nitisinone (Harliku) for the reduction of urine homogentisic acid (HGA) in patients with alkaptonuria (AKU). The FDA approved nitisinone (Harliku) for the reduction of urine homogentisic acid (HGA) in patients with alkaptonuria (AKU). The medication is expected to launch in July 2025. Approximately 67.5% REFERENCES 1.
The Checkup by Singlecare
NOVEMBER 15, 2024
In a study from 2006 , researchers called the combination of amlodipine and losartan “an excellent option for the treatment of a wide range of hypertensive patients.” Additionally, the FDA hasn’t listed any known interactions for the medications on the losartan or amlodipine labels.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
JUNE 27, 2025
For example, the US Food and Drug Administration (FDA), Japanese PMDA and the European Medicines Agency (EMA) are aligning their requirements while minimising risk to patient safety or product quality. Many CGTs have also taken advantage of expedited market entry schemes and exclusivity options.
The Checkup by Singlecare
AUGUST 7, 2025
It was originally approved by the Food and Drug Administration in 2006 for the treatment of asthma in people 12 years and older, and in 2009 for the treatment of chronic obstructive pulmonary disease (COPD). Since then, it has also been approved as an asthma treatment for kids over 6 years of age. gm of 160/4.5 gm of 160/4.5 gm of 160/4.5
PharmTech
JUNE 23, 2025
FDA guidance documents illustrate labeling salt drugs and associated active moieties. The secondary label will specify the Drug ZA-ion amount per capsule and the equivalent Drug Z-salt amount consistent with FDA labeling guidance. Additional mole calculations are needed only for drug-name labeling per FDA guidance ( Figure 5b above).
Pharmacy Times
JUNE 27, 2025
's 2006 study highlighted psilocybin's potential to induce meaningful mystical experiences, sparking renewed research interest. The relevance of the 2006 study by Griffiths et al cannot be overstated. Historical studies, like Grof et al.'s Griffiths et al.'s
Pharmacy Times
AUGUST 4, 2025
2 The only FDA-approved maintenance therapy for MM is lenalidomide, an oral immunomodulatory drug that targets myeloma cells through cereblon binding, enhances immune system function through activation of T cells and natural killer cells, and prevents new myeloma cell growth through inhibition of vascular endothelial growth factor.
Expert insights. Personalized for you.
Let's personalize your content